• +1-646-491-9876
    • +91-20-67278686

    Search

    Medulloblastoma Pipeline Review H1 2017

    Medulloblastoma Pipeline Review H1 2017

    • Report Code ID: RW0001858661
    • Category Pharmaceuticals
    • No. of Pages 141
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Medulloblastoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H1 2017, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

    Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 3 and 13 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

    Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Medulloblastoma - Overview
    Medulloblastoma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Medulloblastoma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Medulloblastoma - Companies Involved in Therapeutics Development
    Bayer AG
    Bristol-Myers Squibb Company
    DelMar Pharmaceuticals Inc
    Ignyta Inc
    IMPACT Therapeutics Inc
    Lipocure Ltd
    MacroGenics Inc
    NewLink Genetics Corp
    Novogen Ltd
    Ono Pharmaceutical Co Ltd
    Progenics Pharmaceuticals Inc
    Stemline Therapeutics Inc
    ThromboGenics NV
    VBI Vaccines Inc
    Medulloblastoma - Drug Profiles
    (topotecan hydrochloride + vincristine sulfate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bispecific Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bispecific Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dianhydrogalactitol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Edotreotide Labeled Yttrium 90 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMP-5471 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    indoximod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ipilimumab + nivolumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride + TBio-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-5 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nifurtimox - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nifurtimox SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nivolumab - Drug Profile
    R&D Progress
    Oncolytic Virus to Target CD46 and SLC5A5 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    p28 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pyrvinium pamoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SL-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    taladegib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    THR-317 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Trilexium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VBI-1901 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIMO-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VMY-1103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Medulloblastoma - Dormant Projects
    Medulloblastoma - Product Development Milestones
    Featured News & Press Releases
    Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
    Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations
    Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
    Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
    Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program
    Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083
    Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant
    Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Medulloblastoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Medulloblastoma - Pipeline by Bayer AG, H1 2017
    Medulloblastoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
    Medulloblastoma - Pipeline by Ignyta Inc, H1 2017
    Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H1 2017
    Medulloblastoma - Pipeline by Lipocure Ltd, H1 2017
    Medulloblastoma - Pipeline by MacroGenics Inc, H1 2017
    Medulloblastoma - Pipeline by NewLink Genetics Corp, H1 2017
    Medulloblastoma - Pipeline by Novogen Ltd, H1 2017
    Medulloblastoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
    Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H1 2017
    Medulloblastoma - Pipeline by ThromboGenics NV, H1 2017
    Medulloblastoma - Pipeline by VBI Vaccines Inc, H1 2017
    Medulloblastoma - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Medulloblastoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Bayer AG
    Bristol-Myers Squibb Company
    DelMar Pharmaceuticals Inc
    Ignyta Inc
    IMPACT Therapeutics Inc
    Lipocure Ltd
    MacroGenics Inc
    NewLink Genetics Corp
    Novogen Ltd
    Ono Pharmaceutical Co Ltd
    Progenics Pharmaceuticals Inc
    Stemline Therapeutics Inc
    ThromboGenics NV
    VBI Vaccines Inc

    Request for Sample

    Report Url http://www.reportsweb.com//medulloblastoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//medulloblastoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//medulloblastoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments